Cerevel Therapeutics Holdings Inc [CERE] stock is trading at $41.23, down -0.29%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CERE shares have gain 4.22% over the last week, with a monthly amount glided 1.20%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Cerevel Therapeutics Holdings Inc [NASDAQ: CERE] stock has seen the most recent analyst activity on December 08, 2023, when TD Cowen downgraded its rating to a Market Perform but kept the price target unchanged to $45 for it. On September 28, 2023, Piper Sandler initiated with a Overweight rating and assigned a price target of $33 on the stock. BofA Securities downgraded its rating to a Neutral and decreased its price target to $31 on August 03, 2023. Wells Fargo upgraded its rating to a Overweight but $30 remained the price target by the analyst firm on May 04, 2023. In a note dated March 17, 2023, JP Morgan downgraded an Neutral rating on this stock and revised its target price from $40 to $29.
Cerevel Therapeutics Holdings Inc [CERE] stock has fluctuated between $19.59 and $43.59 over the past year. Currently, Wall Street analysts expect the stock to reach $33.5 within the next 12 months. Cerevel Therapeutics Holdings Inc [NASDAQ: CERE] shares were valued at $41.23 at the most recent close of the market. An investor can expect a potential drop of -18.75% based on the average CERE price forecast.
Analyzing the CERE fundamentals
Gross Profit Margin for this corporation currently stands at 0.29% with Operating Profit Margin at -59.47%, Pretax Profit Margin comes in at -55.77%, and Net Profit Margin reading is -55.84%. To continue investigating profitability, this company’s Return on Assets is posted at -0.41, Equity is -0.99 and Total Capital is -0.47. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.65.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 41.02 points at the first support level, and at 40.82 for the second support level. However, for the 1st resistance point, the stock is sitting at 41.36, and for the 2nd resistance point, it is at 41.50.
Ratios To Look Out For
For context, Cerevel Therapeutics Holdings Inc’s Current Ratio is 10.22. In addition, the Quick Ratio stands at 10.22 and the Cash Ratio stands at 3.81.
Transactions by insiders
Recent insider trading involved COLES N ANTHONY, Director, that happened on Jun 03 ’24 when 50000.0 shares were sold. Director, COLES N ANTHONY completed a deal on May 10 ’24 to sell 50000.0 shares. Meanwhile, Director COLES N ANTHONY sold 50000.0 shares on Apr 01 ’24.
